| Literature DB >> 25505208 |
R Michael Tuttle1, Robert I Haddad1, Douglas W Ball1, David Byrd1, Paxton Dickson1, Quan-Yang Duh1, Hormoz Ehya1, Megan Haymart1, Carl Hoh1, Jason P Hunt1, Andrei Iagaru1, Fouad Kandeel1, Peter Kopp1, Dominick M Lamonica1, William M Lydiatt1, Judith McCaffrey1, Jeffrey F Moley1, Lee Parks1, Christopher D Raeburn1, John A Ridge1, Matthew D Ringel1, Randall P Scheri1, Jatin P Shah1, Steven I Sherman1, Cord Sturgeon1, Steven G Waguespack1, Thomas N Wang1, Lori J Wirth1, Karin G Hoffmann1, Miranda Hughes1.
Abstract
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25505208 DOI： 10.6004/jnccn.2014.0169
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908